In a flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (trans-3-hydroxy-cyclobutyl)-amide (100 mg, 0.20 mmol) was dissolved in dichloromethane (1.0 mL). Trifluoroacetic acid (0.61 mL, 7.92 mmol) was added and the orange solution was stirred at room temperature for 2 h. The reaction mixture was concentrated. The residue (light orange foam) was suspended in dichloromethane (1.0 mL) and ethylenediamine (0.80 ml, 11.8 mmol) was added. The light yellow suspension was stirred at room temperature for 1 h. The reaction mixture was diluted with water and ethyl acetate. The suspension was filtered and washed with water (hot) and ethyl acetate. The resulting off-white powder was dried under high vacuum to provide 55 mg (66%; purity=90%) 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (trans-3-hydroxycyclobutyl)-amide. LC/MS: [M−H]−=379. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 12.31-12.64 (br. s., 1H), 9.10 (s, 1H), 8.52 (dd, J=9.0, 5.2 Hz, 1H), 8.43 (s, 1H), 8.36 (d, J=7.1 Hz, 1H), 7.72 (dd, J=9.7, 2.1 Hz, 1H), 7.20 (td, J=9.1, 2.3 Hz, 1H), 5.19-5.26 (m, 1H), 4.52-4.61 (m, 1H), 4.44-4.61 (m, 1H), 4.16 (s, 3H), 2.25-2.40 (m, 4H).
